معرفی
Jonas Eriksson is a Visiting Researcher at the Department of Medicinal Chemistry, Preparative Medicinal Chemistry at Uppsala University, where he works as a senior researcher in radiopharmaceutical chemistry at the Uppsala University Hospital PET centre. His career spans institutions across Sweden and the Netherlands, with significant contributions to the field of PET imaging and radiopharmaceutical development.
- PhD in Chemistry from Uppsala University (2006), thesis on '11C-chemistry for Positron Emission Tomography (PET)'
- Postdoctoral position at VU University Amsterdam with Professor Bert Windhorst
- Permanent position at PET research department at VUmc Amsterdam
- Since 2012: Senior researcher at Uppsala University Hospital PET centre
Eriksson's research focuses on radiopharmaceutical chemistry and PET tracer development, with particular emphasis on carbon-11 and fluorine-18 labeled compounds for neuroimaging, oncology, and metabolic disorders. His work bridges synthetic radiochemistry with preclinical and clinical applications, developing novel methods for radiolabeling antibodies, peptides, and small molecules. Recent work demonstrates expertise in Affibody molecule engineering, bispecific antibodies for brain delivery, and imaging of amyloid-beta, tau pathology, and fibrogenesis.
Analysis of Eriksson's recent publications (2023-2025) reveals a strong focus on advancing molecular imaging techniques with applications across multiple disease areas. His work spans neurodegenerative disorders (Alzheimer's, Parkinson's), metabolic diseases (diabetes), and fibrotic conditions. A notable trend is the development of innovative radiolabeling techniques for proteins and antibodies, particularly using RESCA chemistry and tetrazine-based pretargeting strategies. His research group is actively working on improving brain penetration of imaging agents and developing more specific tracers for various molecular targets.
Eriksson collaborates extensively with researchers across Uppsala University and internationally, contributing to the development of novel imaging biomarkers with both diagnostic and therapeutic monitoring applications. His work on the Uppsala APP mutation mouse model has provided important insights into amyloid-beta structure and its relationship to neuroinflammation.
